DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites

Protein–protein interactions represent an exciting and challenging target class for therapeutic intervention using small molecules. Protein interaction sites are often devoid of the deep surface pockets presented by “traditional” drug targets, and crystal structures reveal that inhibitors typically...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of medicinal chemistry 2016-05, Vol.59 (9), p.4152-4170
Main Authors:	Gowthaman, Ragul, Miller, Sven A, Rogers, Steven, Khowsathit, Jittasak, Lan, Lan, Bai, Nan, Johnson, David K, Liu, Chunjing, Xu, Liang, Anbanandam, Asokan, Aubé, Jeffrey, Roy, Anuradha, Karanicolas, John
Format:	Article
Language:	eng
Subjects:	Humans Molecular Docking Simulation Myeloid Cell Leukemia Sequence 1 Protein - chemistry Protein Binding Protein Conformation Surface Properties
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Protein–protein interactions represent an exciting and challenging target class for therapeutic intervention using small molecules. Protein interaction sites are often devoid of the deep surface pockets presented by “traditional” drug targets, and crystal structures reveal that inhibitors typically engage these sites using very shallow binding modes. As a consequence, modern virtual screening tools developed to identify inhibitors of traditional drug targets do not perform as well when they are instead deployed at protein interaction sites. To address the need for novel inhibitors of important protein interactions, here we introduce an alternate docking strategy specifically designed for this regime. Our method, termed DARC (Docking Approach using Ray-Casting), matches the topography of a surface pocket “observed” from within the protein to the topography “observed” when viewing a potential ligand from the same vantage point. We applied DARC to carry out a virtual screen against the protein interaction site of human antiapoptotic protein Mcl-1 and found that four of the top-scoring 21 compounds showed clear inhibition in a biochemical assay. The K i values for these compounds ranged from 1.2 to 21 μM, and each had ligand efficiency comparable to promising small-molecule inhibitors of other protein–protein interactions. These hit compounds do not resemble the natural (protein) binding partner of Mcl-1, nor do they resemble any known inhibitors of Mcl-1. Our results thus demonstrate the utility of DARC for identifying novel inhibitors of protein–protein interactions.
ISSN:	0022-2623 1520-4804